STRATA Skin Sciences(US:SSKN)2022-03-20 10:36Business Overview - Strata is positioned for growth acceleration in the treatment of chronic skin conditions, addressing large markets with differentiated laser-based treatments[4,6] - The company operates with a recurring revenue model, driven by repeat and sustainable revenues, and has a customer base of approximately 1,000 partner practices[4] - Strata is expanding its international presence in key markets and recent product acquisitions are opening significant growth opportunities[4] Clinical and Treatment - Psoriasis treatments remain the primary use for XTRAC lasers domestically, accounting for 80% of treatments, with opportunities to expand use for vitiligo and atopic dermatitis[13,14] - A multicenter psoriasis study showed that 72% of patients achieved at least 75% clearing in an average of 62 treatments[21] - A vitiligo study showed that 506% of treated patches achieved 75% or more pigmentation, and 255% achieved 100% pigmentation[21] Financial Performance and Growth - Preliminary unaudited total revenue for the full year 2021 is expected to range from $297 million to $301 million, compared to $231 million for the full year 2020[51] - The company's installed base has grown by 25% over the last 3 years, driven by actively redeploying underutilized devices and strategic placements[29] - International partner XTRAC clinics increased to 54 in 2021, up from 28 in 2020 and 10 in 2019[51] Acquisitions and Market Expansion - Strata acquired the U S Dermatology Business of Ra Medical Systems, converting 30 of 73 Pharos users through 12/31/2021[41,43] - The acquisition of Theraclear broadens Strata's opportunity in the estimated $55 billion acne care market[45]